Brief: Context Therapeutics And Menarini Group Announce Clinical Trial Collaboration And Supply Agreement To Evaluate Ona-Xr And Elacestrant Combination
02/08/2022 12:51
Aug 2 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS AND MENARINI GROUP ANNOUNCE CLINICAL
TRIAL
COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE ONA-XR AND
ELACESTRANT COMBINATION
* CONTEXT THERAPEUTICS - CONTEXT TO INITIATE PHASE 1B/2
CLINICAL
TRIAL IN Q4 2022
* CONTEXT THERAPEUTICS - CONTEXT WILL SPONSOR CLINICAL TRIAL
AND
MENARINI WILL SUPPLY ELACESTRANT AT NO COST
Source text for Eikon: ID:nGNX6y72Zb
Further company coverage: CNTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202